But the Exelixis growth story is about more than just Cabometyx's quest to dominate RCC and HCC. It's about innovation. Cabometyx is currently being studied in around six dozen clinical trials, some of which are being conducted in combination with other therapies. One of these studies, CheckMate 9ER, which was undertaken in combination with Bristol Myers Squibb 's Opdivo, met statistical significance in treating first-line advanced RCC patients. Years from now, Cabometyx might well be capable of $2 billion-plus in annual sales.